Expression of glucose transporter protein 1 and p63 in serous ovarian tumor

Cai, Yu; Zhai, Jianjun; Feng, Bibo; Duan, Xiaohui; He, Xiaojin

doi:10.1111/jog.12447

Cited by 15 publications

(16 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found a gradual increase in staining intensity of GLUT-1 from borderline to malignant tumors with a statistically significant difference supporting that the expression of this transporter may be closely related to the malignant transformation of epithelial ovarian tumors. Our findings agreed with results of other studies (3,7,8,9,10,12).…”

Section: Discussionsupporting

confidence: 93%

“…As regard the FIGO staging, there has been significant correlation with staining intensity for GLUT-1 (P = 0.01) which agreed with other authors (4,7,11). On the other hand, Canturia et al (14) found no statistical association between GLUT-1 expression levels and FIGO staging.…”

Section: Discussionsupporting

confidence: 85%

“…GLUT-1 is a representative of a family of 14 closely related proteins known as glucose transporters that mediates glucose transport across cell membrane. The published studies have shown a close relationship between GLUT-1 expression and carcinogenesis, tumor biology, and the poor prognosis of many cancers (3,4,5,6,7).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Role of GLUT-1 immunostaining in Diagnosis and prognosis of ovarian carcinoma.

Nagib

Hemida

Wageh

2016

The Egypt. J. of Fert.y of Steri.

View full text Add to dashboard Cite

Background: close relationship between GLUT-1 expression and carcinogenesis, tumor development, and the unfavorable prognosis of several malignant tumors. Objective: To investigate the correlation of GLUT-1 immunostaining and clinic-pathologic features as well as prognosis of ovarian cancer patients. Materials and methods: Paraffin blocks of 76 cases were retrieved from archives of pathology department, Mansoura University. These included 57 cases with malignant ovarian tumors, 11 cases with benign ovarian tumors, and 8 cases with borderline ovarian tumors. The sectioned samples were stained with polyclonal antibody for GLUT-1. The degree of immunostaining were correlated with clinic-pathologic features as well as prognosis of ovarian cancer patients. Results: All benign tumors were negative for GLUT-1. Strong staining reaction for GLUT-I was significantly associated with the malignant phenotype (p=0.0001). Moreover, there was a statistically significant difference in staining intensity for GLUT-1 between borderline and malignant tumors (p=0.0028). There was a statistically significant correlation between high grade tumors and strong staining intensity (p=0.001). Correlation between staining reaction for GLUT-1 and developing metastases and/or recurrence was statistically significant (p=0.001). Conclusion: GLUT-1 is related to carcinogenesis of ovarian carcinomas. The statistically significant correlation between staining intensity for GLUT-1 and malignant phenotype can make it a marker for target therapy for ovarian cancer patients. In addition, GLUT-1 can be considered as predictor for metastases and recurrence in ovarian carcinoma that needs to be validated in future trials.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionsupporting

confidence: 85%

See 1 more Smart Citation

Role of GLUT-1 immunostaining in Diagnosis and prognosis of ovarian carcinoma.

Nagib

Hemida

Wageh

2016

The Egypt. J. of Fert.y of Steri.

View full text Add to dashboard Cite

show abstract

“…[3] Of the two different classes of hexose transporters (SGLT: sodium-dependent glucoset ransporter,G LUT:f acilitative glucose transporter [4] )t he GLUTsw ere found to be overexpressed in many tumors. [5] In particular, GLUT1 overexpression has been reported in many types of human cancers, including those of brain, [6] breast, [7] colon, [8] kidney, [9] lung, [10] ovary, [11] and prostate, [12] and is correlated with advanced cancer stages and poor clinicalo utcomes. It was demonstrated that the activation of certain oncogenes like c-myc, [13] KRAS, [10] BRAF, [14] and p53, [15] and transcription factors like hypoxiai nducible factor-1a, [16] can induce the GLUT1 overexpression.…”

Section: Introductionmentioning

confidence: 99%

Identification and Optimization of the First Highly Selective GLUT1 Inhibitor BAY‐876

et al. 2016

View full text Add to dashboard Cite

Despite the long‐known fact that the facilitative glucose transporter GLUT1 is one of the key players safeguarding the increase in glucose consumption of many tumor entities even under conditions of normal oxygen supply (known as the Warburg effect), only few endeavors have been undertaken to find a GLUT1‐selective small‐molecule inhibitor. Because other transporters of the GLUT1 family are involved in crucial processes, these transporters should not be addressed by such an inhibitor. A high‐throughput screen against a library of ∼3 million compounds was performed to find a small molecule with this challenging potency and selectivity profile. The N‐(1H‐pyrazol‐4‐yl)quinoline‐4‐carboxamides were identified as an excellent starting point for further compound optimization. After extensive structure–activity relationship explorations, single‐digit nanomolar inhibitors with a selectivity factor of >100 against GLUT2, GLUT3, and GLUT4 were obtained. The most promising compound, BAY‐876 [N 4‐[1‐(4‐cyanobenzyl)‐5‐methyl‐3‐(trifluoromethyl)‐1H‐pyrazol‐4‐yl]‐7‐fluoroquinoline‐2,4‐dicarboxamide], showed good metabolic stability in vitro and high oral bioavailability in vivo.

show abstract

“…29 However, mixed data regarding p63 status in serous carcinoma has been reported. Whereas some studies have shown that p63 expression may occur in malignant serous carcinomas of the ovary, 30 other studies have suggested that p63 immunoreactivity may actually decrease with malignant progression in serous lesions. 31 In our analysis, only 2 of 17 immunostained cases (12%) of serous carcinoma demonstrated focal p63 expression-one nonproblematic case associated with conventional serous morphology and diffuse WT1 expression, and one more-challenging case that demonstrated nests of carcinoma cells reminiscent of urothelial carcinoma.…”

Section: Analysis Of An Immunohistochemical Panel For Ck7 Wt1 Upiimentioning

confidence: 96%